BioSpace News Archive

Drug Development

Merck’s Keytruda Gets Back-to-Back Phase III Wins in Kidney, Bladder Cancer

The blockbuster immunotherapy secured separate late-stage victories as an adjuvant-setting treatment in renal cell carcinoma and muscle-invasive urothelial carcinoma.

January 29, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Biopharma Invested Just $6.5B in Vaccine Development in Last Decade: Report

The clinical development pipeline for vaccines is broad but shallow with a large proportion of programs dedicated to COVID-19, according to a new report by industry group Biotechnology Innovation Organization.

January 29, 2024
·
2 min read
·
Tristan Manalac
Policy

J&J, Merck CEOs Agree to Testify Before Senate Panel and Dodge Subpoena

The CEOs of J&J and Merck have finally committed to testifying before the Senate health committee regarding the high prices of drugs in the U.S. The hearing is set for Feb. 8.

January 29, 2024
·
2 min read
·
Tristan Manalac
Drug Development

BMS’s Opdivo Fails for Second Time in Late-Stage Kidney Cancer Trial

Bristol Myers Squibb’s PD-1 inhibitor was unable to outperform the placebo arm in improving disease-free survival in renal cell carcinoma patients at high risk of relapse after surgery.

January 29, 2024
·
2 min read
·
Tristan Manalac
Deals

Alto Neuroscience, Fractyl Health Join IPO Surge with Detailed Offering Plans

On the heels of ArriVent and CG Oncology’s upsized IPOs last week, Alto Neuroscience and Fractyl Health on Monday announced their respective plans to go public.

January 29, 2024
·
2 min read
·
Tyler Patchen
Pharm Country

Children’s Hospital of Philadelphia Experts Showcase Frontier Program at Arab Health Exhibition

Showcasing its longstanding partnership with the United Arab Emirates Emirates Health Services, Children’s Hospital of Philadelphia will exhibit thought-leading clinical research in the EHS booth at the Arab Health 2024 Exhibition and Congress, taking place this week in Dubai.

January 29, 2024
·
3 min read
Asieris Presents for the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU

Asieris Pharmaceuticals announced the first-time release of interim analysis data for the Phase II clinical trial of oral APL-1202 in combination with the PD-1 inhibitor tislelizumab for neoadjuvant treatment of muscle-invasive bladder cancer.

January 29, 2024
·
4 min read
Policy

Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Takeda announced that the European Commission approved HYQVIA® [Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase] as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy after stabilization with intravenous immunoglobulin therapy.

January 29, 2024
·
25 min read
Drug Development

Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, a Bladder Cancer Diagnosis and Management Drug, at the 2024 ASCO-GU

Asieris Pharmaceuticals announced the release of Phase III clinical trial data and real-world study data for APL-1706, a bladder cancer diagnosis and management drug, at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium in the form of a poster presentation.

January 29, 2024
·
3 min read
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Alvotech announced positive top-line results from a pharmacokinetic study for AVT03, a biosimilar candidate to Prolia® and Xgeva®, which both contain denosumab.

January 29, 2024
·
8 min read